JAKARTA (Yosefardi) – Pharmaceutical firm PT Merck Sharp Dohme Pharma Tbk (SCPI) expects to book profit next year as no big investment planned for next year.
The big investment has resulted in loss of Rp112 billion in third quarter of last year and Rp9.98 billion loss in the same period of this year. The investment in new plant has impacted positively on the company’s sales growth.
SCPI’s sales in third quarter of this year jumped 141.77% to Rp691.17 billion from Rp285.87 billion in the same period of last year. Gross profit also rose 44.66% to Rp97.72 billion. But the company recorded operating loss of Rp8.71 billion for the period.
SCPI intends to de-listing or become a private company but it still fails to cut public’s shareholdings from current 10.8% to 1.57%.